Lyme disease is the most common of tick-borne illnesses in the United States. It is a multisystem disease caused by infection with Borrelia burgdorferi. One of the complications is carditis, which reportedly ranges between 1% and 10 % of the total Lyme disease cases, occurring within weeks to months of the onset of infection. It presents in the early disseminated stage, the second phase of the disease. The most prominent manifestations are conduction system disturbances involving the atrioventricular (AV) node. This leads to several degrees of heart block that, in some cases, require the placement of a temporary pacemaker.
Other forms of presentation include myocarditis, endocarditis, valvular heart disease, pericarditis, and myopericarditis. However, such conditions have been reported less frequently than the typical conduction system abnormalities.
Lyme disease results from infection with the spirochete Borrelia burgdorferi (B.burgdorferi), named in honor of the microbiologist Dr. Willy Burgdorfer who isolated it in 1982. The natural reservoir for the spirochete includes mice, chipmunks, and other small mammals. Deer are not competent hosts for B.burgdorferi, but they play an important role in sustaining the life cycle of the vector, Ixodes tick, which transmits the spirochete. This tick acquires B.burgdorferi by feeding on an infected animal and may transmit the infection to a human during a subsequent blood meal.
Approximately 30000 cases of Lyme disease are reported annually in the United States; however, the real number can be much higher. In 2015, 95% of cases identified were in the Northeast, mid-Atlantic, and upper Midwest states, and the most affected groups were males between 5 and 9 and 45 to 59 years old. Lyme disease is diagnosed most commonly between March and October, with 60% in June and July. Cardiovascular symptoms are present in approximately 1.5% to 10% of reported cases in the United States. Cases have also been found to be more common in young adult males with a roughly 3 to 1 male: female ratio.
Replication of B. burgdorferi happens at the site of its inoculation after the tick bite. Following this incident, in a period ranging from few days to a month, the innate and adaptive cellular immune response arises locally at the site of spirochete entry. After these events, the spirochete, with the help of several proteins and other substances found in the body, spreads to other tissues, including the central nervous system, eye, muscle, liver, spleen, and the heart.
The immune response activates before and during the organism dissemination. In an attempt to stop this invasion, the body initially activates B-Cell clones with subsequent elevation of IgM levels. Weeks to months later, the production of IgG directed to different components of B. burgdorferi induces complement fixation and opsonization with consequent bactericidal killing.
The exact mechanism leading to cardiac manifestations is not entirely understood. However, it seems to be an autoimmune inflammatory response to the spirochetes present in heart tissue, which causes the abnormalities inducing AV block. It is possible that cross-reactive IgM antibodies can react with cardiac tissue with consequent injury and functional abnormalities. Researchers have also noted that there is a strong correlation between the number of spirochetes in heart tissue, myocardial inflammation, and the degree of conduction abnormalities.
Pathophysiologic events causing Lyme endocarditis are even less clear. No microorganisms usually appear in tissue samples; for this reason, diagnostic confirmation is by other means including serologic tests and polymerase chain reaction(PCR).
The characteristic histopathological finding is an interstitial inflammatory infiltrate containing lymphocytes, histiocytes, and plasma cells. Such infiltrates extend from the endocardium to the epicardium. Neutrophils and eosinophils do not appear in a substantial amount. Spirochetes have been visualized in the epicardium, myocardium, and endocardium with the use of Warthin-Starry stain and also by immunohistochemistry. However, B.burgdorferi is not always identified. In some case reports of Lyme endocarditis, bacteria appear absent in tissue samples and, other diagnostic methods, such as polymerase chain reaction (PCR), have been required to confirm such condition.
The pathology and localization of infiltrates are not known in less severe cases or during earlier stages of infection in humans.
Lyme carditis must be considered in patients with the typical clinical manifestations of Lyme disease, which usually occurs in various stages. The first phase, early localized infection, is recognized by the characteristic erythema migrans. Following the local manifestation, patients may develop generalized symptoms such as malaise, fever and chills, headache, myalgias, arthralgias, and dizziness as the spirochete continues spreading. It is at this time that cardiac manifestations can arise. Most cases of Lyme carditis occur between June and December. Symptoms are developed from four days up to seven months after the initial presentation (such as a rash) with a median of 21 days. Patients may initially present the characteristic signs and symptoms of the disease; however, reports exist indicating that many patients do not recall a tick bite, and the typical rash is present in only 40% of patients with Lyme carditis. The most common symptoms are related to the most common cardiac manifestations, such as heart block, light-headedness, syncope, shortness of breath, palpitations, and/or chest pain.
The most common objective manifestation of Lyme carditis is atrioventricular (AV) conduction block. The degree of AV block can fluctuate rapidly, lie progressing from the first degree AV block to second degree or complete AV block, and sometimes back to first degree AV block just in minutes.
Cases of endocarditis with valvular involvement, pericarditis, and myocarditis attributed to Lyme disease have also appeared in the literature. However, these manifestations are reported less commonly than the characteristic conduction delayed abnormalities.
Cases of myopericarditis present with symptoms and electrocardiographic changes similar to acute coronary syndrome; 60% of those patients will present with T wave inversion or ST-segment depression. It is rare to find patients with high troponin levels and/or ST-segment elevation. Valvular involvement with endocarditis is not common; if that is the case, patients usually exhibit signs of acute heart failure and cardiogenic shock.
Atrioventricular block (AV block) of varying degrees is the most frequent manifestation of Lyme carditis. Therefore, if a patient presents with the characteristic demographic and clinical manifestations, including bradycardia, the next step is to evaluate an electrocardiogram (ECG) carefully. AV block in Lyme carditis may range from first degree to complete heart block, also known as third-degree AV block. In these patients, the degree of AV block may change over minutes, hours, or days.
AV block denotes an abnormal relationship between the P wave and QRS complex. THE first-degree AV block characteristically demonstrates a fixed prolongation of the PR interval (greater than 200 milliseconds). Second-degree AV block displays a progressive prolongation of the PR interval followed by a nonconductive P wave (Mobitz type I) or presents with an unchanged PR interval followed by a single non-conducted P wave (Mobitz type II). In the highest degree of AV block, third degree, there is no atrioventricular conduction, and the ECG shows a dissociation between P waves and QRS complexes. Additional studies are not usually necessary if heart block is the only manifestation of Lyme carditis.
Supplementary studies play a more important role when suspecting valvular disease or myocarditis. A chest X-ray may show bilateral infiltrates or pleural effusions. Echocardiography may show mild left ventricular or right ventricular dilation in cases with predominant conduction abnormalities. However, most of the time, the ventricle size remains preserved. Echocardiography may also play a role in differentiating myocarditis from myocardial infarction. In patients with signs and ECG changes characteristics of the acute coronary syndrome, echocardiography reveals diffuse ventricular hypokinesis as opposed to focal wall motion abnormalities seen in myocarditis. If difficulty in differentiating between these two conditions is present, cardiac MRI merits consideration. In myocarditis, cardiac MRI may show areas of increased epicardial contrast enhancement with no subendocardial involvement, as seen in acute coronary syndrome.
The gold standard to diagnose infectious diseases continues to be the isolation of the offending pathogen; this is not the case of B. burgdorferi, which, like some other spirochetes, cannot be cultivated. The diagnosis is based on indirect serologic tests in addition to clinical suspicion and supporting laboratory and imaging tests. In many cases, clinical suspicion alone may warrant antibiotic treatment. However, many patients may not present the typical manifestations or symptoms may be ambiguous. A two-step method of serologic testing is suggested as the approach to follow. Enzyme-linked immunosorbent assay (ELISA) is the first test to be considered. If IgM or IgG is positive or borderline, Western Blot assay is required to confirm the diagnosis. Also, B. burgdorferi DNA has been detected in heart tissue by PCR. PCR can be obtained if the suspected cause of myocarditis or endocarditis is Lyme disease and if the serologic tests for this condition are negative or equivocal when the suspicion is high.
Even though some cases of Lyme carditis can resolve without treatment, antibiotics are indicated to lower the risk of cardiovascular complications, avoid sequela, and shorten the duration of the disease. Beta-lactam antibiotics with demonstrated effectiveness against B. burgdorferi include cephalosporins and tetracyclines. For mild to moderate disease, oral amoxicillin or doxycycline is indicated for 14 to 21 days.
Patients with more severe disease require hospitalization. Criteria to admit patients include:
1) Presence of symptoms such as syncope, dyspnea, or chest pain
2) AV block of the second or third-degree
3) AV block of first degree with P-R interval greater than or equal to 300 ms.
Although there is no evidence indicating the superiority of treatment with parenteral over oral antibiotics, parenteral treatment is the general recommendation for initial treatment in hospitalized patients. Ceftriaxone or cefotaxime is the usual recommended parenteral antibiotics. Intravenous antibiotics should continue until the resolution of second or third-degree AVB or until the P-R interval shortens to under 300 ms. Patients may later continue oral therapy to complete a complete course of 14 to 21 days.
Temporary pacemaker placement is indicated in patients with a combination of hemodynamic instability and high-grade second or third-degree AVB to avoid. The pacemaker can be removed once the high-degree heart block has been resolved.
Since conduction disturbances are transient, resolve with antibiotic treatment, and are not expected to recur, permanent pacemaker placement is not a recommendation. The 2008 American College of Cardiology/American Heart Association/Heart rhythm society Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities points Lyme carditis out as a class 3 indication.
Lyme carditis generally has a good prognosis. It is usually associated with conduction disturbances and is, most of the time, a treatable condition. With adequate antibiotic treatment, the recovery time of patients with third-degree heart block has a median of six days. Some cases of persistent AV block exist, but they are extremely rare. There are reports of death secondary to severe myocarditis. However, there are only a few documented cases with this outcome.
Reports exist of fatal cases; nevertheless, the mortality rate associated with Lyme carditis has always been low and has declined even more as early identification and subsequent antibiotic treatment has improved over time. There was a published report of three deaths associated with Lyme carditis in 2013. After this publication, the CDC directed a follow-up investigation, which included 1696 cases reported between 1995 and 2013. Of the three cases, only two were confirmed as Lyme carditis-associated mortality, this account for 0.001% of the total.
If traveling to endemic areas, minimizing the contact with tick can be achieved by:
Antibiotic prophylaxis with oral doxycycline 200 mg is the recommended course for individuals with tick attachment for at least 36 hours.
Medical evaluation is necessary for people who develop a rash in the site of tick attachment, multiple skin lesions, or generalized flu-like symptoms.
Patients with Lyme disease, in general, are managed by an interprofessional team because of its diverse presentation and difficulty in diagnosis. The majority of cases are manageable by the primary caregiver, nurse practitioner, and internist as part of an interprofessional team. However, Lyme carditis is best managed by an infectious disease expert and a cardiologist. While the condition usually resolves, close monitoring is necessary as some patients may require temporary pacing.
Lyme disease is best prevented. Primary care clinicians and nurses should work together to provide patient and family education in endemic areas.
Even though Lyme carditis occurs in only a small percentage of patients with Lyme disease, significant consequences can develop. Thus, people going to or living in endemic areas require education regarding protective measurements. Hikers should wear appropriate garments and know how to remove the tick.
If symptoms develop, immediate medical evaluation and assistance is a prudent course of action. Medical providers must have a high clinical suspicion of the disease taking into account epidemiological risk factors. If the suspicious index is high, further serologic testing is necessary for confirmation. Prompt treatment is required in established cases as the resolution rate is high if actions take place with no delay.
A team approach to Lyme carditis can greatly facilitate diagnosis and help prevent complications. The infectious disease specialist and cardiologist should work collaboratively and keep the family physician in the loop. Nursing will administer IV antibiotics and monitor treatment progression, vital signs, and potential mediation adverse effects, and report any status changes to the physician in charge. The pharmacist will verify all dosing, check agent selection against antibiograms, and perform medication reconciliation to avoid drug-drug interactions, communicating to the team regarding any concerns that may arise. Nursing will be responsible for monitoring the patient, assessing compliance with therapy, answering patient questions, and reporting their findings back to the team. [Level 5]
|||Bush LM,Vazquez-Pertejo MT, Tick borne illness-Lyme disease. Disease-a-month : DM. 2018 May; [PubMed PMID: 29402399]|
|||Kostić T,Momčilović S,Perišić ZD,Apostolović SR,Cvetković J,Jovanović A,Barać A,Šalinger-Martinović S,Tasić-Otašević S, Manifestations of Lyme carditis. International journal of cardiology. 2017 Apr 1; [PubMed PMID: 28082088]|
|||Paim AC,Baddour LM,Pritt BS,Schuetz AN,Wilson JW, Lyme Endocarditis. The American journal of medicine. 2018 Sep; [PubMed PMID: 29605416]|
|||Koene R,Boulware DR,Kemperman M,Konety SH,Groth M,Jessurun J,Eckman PM, Acute heart failure from lyme carditis. Circulation. Heart failure. 2012 Mar 1 [PubMed PMID: 22438525]|
|||Maher B,Murday D,Harden SP, Cardiac MRI of Lyme disease myocarditis. Heart (British Cardiac Society). 2012 Feb [PubMed PMID: 22082689]|
|||Muehlenbachs A,Bollweg BC,Schulz TJ,Forrester JD,DeLeon Carnes M,Molins C,Ray GS,Cummings PM,Ritter JM,Blau DM,Andrew TA,Prial M,Ng DL,Prahlow JA,Sanders JH,Shieh WJ,Paddock CD,Schriefer ME,Mead P,Zaki SR, Cardiac Tropism of Borrelia burgdorferi: An Autopsy Study of Sudden Cardiac Death Associated with Lyme Carditis. The American journal of pathology. 2016 May; [PubMed PMID: 26968341]|
|||Kwit NA,Nelson CA,Max R,Mead PS, Risk Factors for Clinician-Diagnosed Lyme Arthritis, Facial Palsy, Carditis, and Meningitis in Patients From High-Incidence States. Open forum infectious diseases. 2018 Jan; [PubMed PMID: 29326960]|
|||Yeung C,Baranchuk A, Systematic Approach to the Diagnosis and Treatment of Lyme Carditis and High-Degree Atrioventricular Block. Healthcare (Basel, Switzerland). 2018 Sep 22; [PubMed PMID: 30248981]|
|||Ciesielski CA,Markowitz LE,Horsley R,Hightower AW,Russell H,Broome CV, Lyme disease surveillance in the United States, 1983-1986. Reviews of infectious diseases. 1989 Sep-Oct; [PubMed PMID: 2682955]|
|||Bruyn GA,De Koning J,Reijsoo FJ,Houtman PM,Hoogkamp-Korstanje JA, Lyme pericarditis leading to tamponade. British journal of rheumatology. 1994 Sep; [PubMed PMID: 8081675]|
|||Leonelli FM,De Ponti R,Bagliani G, Challenges in Bradicardias Interpretation. Cardiac electrophysiology clinics. 2019 Jun [PubMed PMID: 31084850]|
|||Munk PS,Ørn S,Larsen AI, Lyme carditis: persistent local delayed enhancement by cardiac magnetic resonance imaging. International journal of cardiology. 2007 Feb 14 [PubMed PMID: 16904215]|
|||Robinson ML,Kobayashi T,Higgins Y,Calkins H,Melia MT, Lyme carditis. Infectious disease clinics of North America. 2015 Jun; [PubMed PMID: 25999222]|
|||Krause PJ,Bockenstedt LK, Cardiology patient pages. Lyme disease and the heart. Circulation. 2013 Feb 19; [PubMed PMID: 23429899]|
|||Muhammad S,Simonelli RJ, Lyme Carditis: A Case Report and Review of Management. Hospital pharmacy. 2018 Jul; [PubMed PMID: 30038446]|
|||Wormser GP,Dattwyler RJ,Shapiro ED,Halperin JJ,Steere AC,Klempner MS,Krause PJ,Bakken JS,Strle F,Stanek G,Bockenstedt L,Fish D,Dumler JS,Nadelman RB, The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Nov 1 [PubMed PMID: 17029130]|
|||Sigal LH, Early disseminated Lyme disease: cardiac manifestations. The American journal of medicine. 1995 Apr 24 [PubMed PMID: 7726189]|
|||Epstein AE,DiMarco JP,Ellenbogen KA,Estes NA 3rd,Freedman RA,Gettes LS,Gillinov AM,Gregoratos G,Hammill SC,Hayes DL,Hlatky MA,Newby LK,Page RL,Schoenfeld MH,Silka MJ,Stevenson LW,Sweeney MO,Smith SC Jr,Jacobs AK,Adams CD,Anderson JL,Buller CE,Creager MA,Ettinger SM,Faxon DP,Halperin JL,Hiratzka LF,Hunt SA,Krumholz HM,Kushner FG,Lytle BW,Nishimura RA,Ornato JP,Page RL,Riegel B,Tarkington LG,Yancy CW, ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2008 May 27 [PubMed PMID: 18498951]|
|||Yoon EC,Vail E,Kleinman G,Lento PA,Li S,Wang G,Limberger R,Fallon JT, Lyme disease: a case report of a 17-year-old male with fatal Lyme carditis. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2015 Sep-Oct [PubMed PMID: 25864163]|
|||Three sudden cardiac deaths associated with Lyme carditis - United States, November 2012-July 2013. MMWR. Morbidity and mortality weekly report. 2013 Dec 13 [PubMed PMID: 24336130]|
|||Forrester JD,Meiman J,Mullins J,Nelson R,Ertel SH,Cartter M,Brown CM,Lijewski V,Schiffman E,Neitzel D,Daly ER,Mathewson AA,Howe W,Lowe LA,Kratz NR,Semple S,Backenson PB,White JL,Kurpiel PM,Rockwell R,Waller K,Johnson DH,Steward C,Batten B,Blau D,DeLeon-Carnes M,Drew C,Muehlenbachs A,Ritter J,Sanders J,Zaki SR,Molins C,Schriefer M,Perea A,Kugeler K,Nelson C,Hinckley A,Mead P, Notes from the field: update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death--United States. MMWR. Morbidity and mortality weekly report. 2014 Oct 31 [PubMed PMID: 25356607]|